INHIBITORS OF INFLUENZA VIRUSES REPLICATION
3 Assignments
0 Petitions
Accused Products
Abstract
Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I):
or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.
18 Citations
63 Claims
- 1. A compound represented by Structural Formula (I):
-
3. (canceled)
-
4. (canceled)
-
5. (canceled)
-
7. (canceled)
-
8. (canceled)
-
10. (canceled)
-
12. (canceled)
-
13. (canceled)
-
14. (canceled)
-
16. (canceled)
-
17. (canceled)
-
19. (canceled)
-
21. (canceled)
-
22. (canceled)
-
24. (canceled)
-
25. (canceled)
-
26. (canceled)
-
28. (canceled)
-
29. (canceled)
-
30. (canceled)
-
34. (canceled)
-
35. (canceled)
-
36. (canceled)
-
37. (canceled)
-
39. (canceled)
- 41. (canceled)
-
42. The compound of claim 23, wherein Ring T is selected from:
-
42-1. (canceled)
-
44. (canceled)
-
45. (canceled)
-
46. (canceled)
-
47. (canceled)
-
48. A compound selected from any of one of the structures depicted below:
-
49. A compound selected from any of one of the structures depicted below:
-
52. (canceled)
-
53. (canceled)
-
57. (canceled)
-
60. (canceled)
Specification